Headlines

The transformative potential of combining antibody-drug conjugates with immunotherapy

WHITEPAPER

The transformative potential of
combining antibody-drug
conjugates with immunotherapy

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer.

Precision medicine has improved the prognosis for patients with advanced non-small cell lung cancer (aNSCLC), inspiring research aimed at developing innovative combination treatments. Today there are 10 known genetic alterations that drive aNSCLC. Therapies targeting these alterations, including an antibody drug conjugate (ADC) for HER2-positive tumors, have significantly improved response rates, progression-free survival and overall survival. For patients without targetable genetic alterations, immune checkpoint inhibitors (ICIs) are frequently used as first-line treatments, though options remain limited. The effectiveness of these drugs has inspired oncology researchers to explore whether combining ADCs with ICIs could improve treatment outcomes in patients with aNSCLC. Clinical trials designed to answer key questions about the safety and effectiveness of this strategy are now underway.

Fill out the form below to download

    Clear Form